These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38265476)

  • 1. The Effect of Nabiximols on Driving Ability in Adults with Chronic Tic Disorders: Results of a Substudy Analysis of the Double-Blind, Randomized, Placebo-Controlled CANNA-TICS Trial.
    Müller-Vahl KR; Pisarenko A; Ringlstetter R; Cimpianu CL; Fremer C; Weidinger E; Jenz EB; Musil R; Brunnauer A; Großhennig A
    Cannabis Cannabinoid Res; 2024 Oct; 9(5):1349-1359. PubMed ID: 38265476
    [No Abstract]   [Full Text] [Related]  

  • 2. The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders.
    Jakubovski E; Pisarenko A; Fremer C; Haas M; May M; Schumacher C; Schindler C; Häckl S; Aguirre Davila L; Koch A; Brunnauer A; Cimpianu CL; Lutz B; Bindila L; Müller-Vahl K
    Front Psychiatry; 2020; 11():575826. PubMed ID: 33324255
    [No Abstract]   [Full Text] [Related]  

  • 3. CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders - Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study.
    Müller-Vahl KR; Pisarenko A; Szejko N; Haas M; Fremer C; Jakubovski E; Musil R; Münchau A; Neuner I; Huys D; van Elst LT; Schröder C; Ringlstetter R; Koch A; Jenz EB; Großhennig A
    Psychiatry Res; 2023 May; 323():115135. PubMed ID: 36878177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential impact of COVID-19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA-TICS study.
    Lasch F; Guizzaro L; Aguirre Dávila L; Müller-Vahl K; Koch A
    Pharm Stat; 2021 May; 20(3):675-691. PubMed ID: 33594741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Riva N; Mora G; Sorarù G; Lunetta C; Ferraro OE; Falzone Y; Leocani L; Fazio R; Comola M; Comi G;
    Lancet Neurol; 2019 Feb; 18(2):155-164. PubMed ID: 30554828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome.
    Szejko N; Saramak K; Lombroso A; Müller-Vahl K
    Neurol Neurochir Pol; 2022; 56(1):28-38. PubMed ID: 34708399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray.
    Schwittay MA; Steinbrecher A; Lobsien E
    Tremor Other Hyperkinet Mov (N Y); 2021; 11():33. PubMed ID: 34430070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.
    Bhardwaj AK; Allsop DJ; Copeland J; McGregor IS; Dunlop A; Shanahan M; Bruno R; Phung N; Montebello M; Sadler C; Gugusheff J; Jackson M; Luksza J; Lintzeris N;
    BMC Psychiatry; 2018 May; 18(1):140. PubMed ID: 29776349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain.
    Lichtman AH; Lux EA; McQuade R; Rossetti S; Sanchez R; Sun W; Wright S; Kornyeyeva E; Fallon MT
    J Pain Symptom Manage; 2018 Feb; 55(2):179-188.e1. PubMed ID: 28923526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis.
    Bethoux FA; Farrell R; Checketts D; Sahr N; Berwaerts J; Alexander JK; Skobieranda F
    Mult Scler Relat Disord; 2024 Sep; 89():105740. PubMed ID: 39106541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Online remote behavioural intervention for tics in 9- to 17-year-olds: the ORBIT RCT with embedded process and economic evaluation.
    Hollis C; Hall CL; Khan K; Le Novere M; Marston L; Jones R; Hunter R; Brown BJ; Sanderson C; Andrén P; Bennett SD; Chamberlain LR; Davies EB; Evans A; Kouzoupi N; McKenzie C; Heyman I; Kilgariff J; Glazebrook C; Mataix-Cols D; Serlachius E; Murray E; Murphy T
    Health Technol Assess; 2023 Oct; 27(18):1-120. PubMed ID: 37924247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
    Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS
    JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.
    Trigo JM; Soliman A; Quilty LC; Fischer B; Rehm J; Selby P; Barnes AJ; Huestis MA; George TP; Streiner DL; Staios G; Le Foll B
    PLoS One; 2018; 13(1):e0190768. PubMed ID: 29385147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
    Filippini G; Minozzi S; Borrelli F; Cinquini M; Dwan K
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013444. PubMed ID: 35510826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial.
    Fairhurst C; Kumar R; Checketts D; Tayo B; Turner S
    Dev Med Child Neurol; 2020 Sep; 62(9):1031-1039. PubMed ID: 32342496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols.
    Kanaan AS; Jakubovski E; Müller-Vahl K
    Brain Sci; 2017 Apr; 7(5):. PubMed ID: 28445405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial.
    Coffey B; Jankovic J; Claassen DO; Jimenez-Shahed J; Gertz BJ; Garofalo EA; Stamler DA; Wieman M; Savola JM; Gordon MF; Alexander JK; Barkay H; Harary E
    JAMA Netw Open; 2021 Oct; 4(10):e2129397. PubMed ID: 34661664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome.
    Abi-Jaoude E; Bhikram T; Parveen F; Levenbach J; Lafreniere-Roula M; Sandor P
    Cannabis Cannabinoid Res; 2023 Oct; 8(5):835-845. PubMed ID: 36040329
    [No Abstract]   [Full Text] [Related]  

  • 19. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
    McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
    Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.
    Portenoy RK; Ganae-Motan ED; Allende S; Yanagihara R; Shaiova L; Weinstein S; McQuade R; Wright S; Fallon MT
    J Pain; 2012 May; 13(5):438-49. PubMed ID: 22483680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.